Matt Young is a seasoned research science professional with over 20 years of experience, currently serving as the Scientific Co-Founder and Consultant at Nynex Therapeutics. In this pivotal role, he is at the forefront of pioneering innovative oncology therapeutics that harness the power of cellular...
Matt Young is a seasoned research science professional with over 20 years of experience, currently serving as the Scientific Co-Founder and Consultant at Nynex Therapeutics. In this pivotal role, he is at the forefront of pioneering innovative oncology therapeutics that harness the power of cellular protein degradation pathways. His work focuses on developing first-in-class reversible-covalent compounds aimed at targeting deubiquitinase proteins, a novel approach that holds significant promise for advancing cancer treatment.
At Nynex Therapeutics, Matt leads key projects that integrate advanced computational chemistry with experimental methodologies, enabling the identification and optimization of small-molecule therapeutics. His expertise in bioinformatics and molecular cloning complements his hands-on experience with protein expression and liquid chromatography-mass spectrometry (LC-MS), allowing for a comprehensive understanding of complex biological mechanisms. This multidisciplinary approach not only accelerates the drug discovery process but also enhances the potential for creating effective new medicines.
In addition to his technical skills, Matt is known for his strong team leadership capabilities, fostering collaboration among scientists and researchers to drive innovation. His commitment to unraveling the intricacies of oncology has positioned Nynex Therapeutics as a leader in the field, with a focus on developing therapies that can significantly improve patient outcomes. As the landscape of cancer treatment continues to evolve, Matt Young remains dedicated to leveraging his extensive experience and expertise to contribute to groundbreaking advancements in the life sciences sector.
